TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Received vedolizumab (excluding comparator or placebo participants) during participation in a qualifying vedolizumab study.~2. In the opinion of the investigator, the participant is continuing to derive benefit from vedolizumab and continued treatment with vedolizumab is desired because there is no other comparable product available or the participant may be expected to develop worsening of disease if they were to modify treatment.~3. A male participant who is non-sterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.~4. A female participant of childbearing potential who is sexually active with a non-sterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.~Exclusion Criteria:~1. For the participant's particular clinical scenario, vedolizumab is currently available to the participant through commercial channels, including reimbursement.~2. Has any clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with the dosing requirements or poses a risk to the participant being in the study.~3. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.~4. If male, the participant intends to donate sperm during the course of this study or for 18 weeks thereafter.~5. Has received a live vaccine in the last 18 weeks or is in need of a live vaccine during the study or up to 18 weeks after the last study dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab 300 mg (Type: EXPERIMENTAL): Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) that maybe reduced to once every 4 weeks (Q4W) based on the investigator's judgment of participant's clinical status and acknowledged by the medical monitor for up to 6 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Compression Spot Mammography

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women 45 years and older~* Women with suspicious mammography findings requiring a biopsy~Exclusion Criteria:~* Men~* Pregnant women

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immersive Virtual Reality Based Training for Rehabilitation of Subacute Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. having had an ischemic stroke in the first time~2. age 30 to 80 years old~3. first stroke within 2 month~4. GCS score \>8~5. the upper-limb function BrunnstromⅡ、Ⅲ~Exclusion Criteria:~1. hemorrhage or transient ischemic attack(TIA)~2. important organs such as heart, lung, liver, kidney function decline or failure~3. previous history of brain neurosurgery or epilepsy~4. had severe cognitive impairments or aphasia, which made the participants unable to understand the instructions given by the investigators~5. with claustrophobia and body with metal (such as metal teeth, etc.) are not suitable for to MRI scanning

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- The intervention group (Type: EXPERIMENTAL): The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
- The control group (Type: OTHER): The control group will receive for traditional rehabilitation training for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic and Microbial Profiling of Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age \>18 years, of all racial and ethnic origins, with suspected nonsmall cell lung cancer stages I, II, and III, as evident through radiographic evidence and felt acceptable to undergo surgical resection.~* Patients who have the ability to understand and the willingness to sign a written consent form.~Exclusion Criteria:~* Patients who are have taken antibiotics within two weeks.~* Patients who are on continuous supplemental oxygen.~* Patients currently undergoing active treatment for other malignancies.~* Subjects who are unable or unwilling to provide consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Female Participants (Type: EXPERIMENTAL): 45 female patients will be screened to participate.
- Male Participants (Type: EXPERIMENTAL): 45 male patients will be screened to participate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: MMRF CureCloud Research Initiative

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with active Multiple Myeloma~2. Patients have signed an online consent form~Exclusion Criteria:~1. Patients who live outside the United States~2. Patients with a diagnosis other than Multiple Myeloma or a known or suspected precursor to Multiple Myeloma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CureCloud Direct to Patient (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject was male, 16 years of age or older (18 years of age or older in the US), and post pubertal,(minimum age by region)~2. Subject had a confirmed diagnosis of classic Fabry disease based on deficient AGA enzyme activity (defined as \< 1% of normal).~Exclusion Criteria:~1. Subject had a galactosidase alpha (GLA) gene mutation associated with late-onset cardiac variant Fabry disease.~2. Subject had previously received ERT and/or chaperone therapy within 3 years for treatment of Fabry disease.~3. Subject had tested positive for anti-AGA antibodies at the time of screening.~4. Subject had eGFR \< 60 mL/min/1.73 m² (ie, chronic kidney disease \[CKD\] stage ≥ 3) at Screening.~5. Subject had a prior history of myocardial infarction (MI).~6. Subject had a history of coronary artery disease (CAD) with angina requiring percutaneous transluminal coronary angioplasty (with or without stent placement) and/or coronary artery bypass graft (CABG).~7. Subject had a history of moderate to severe valvular heart disease requiring valve replacement.~8. Subject had a history of heart failure, moderate to severe diastolic dysfunction, and/or left ventricular ejection fraction (LVEF) ≤ 45% on echocardiogram (ECHO) performed at rest at Screening.~9. Subject had a history of clinically significant cardiac arrhythmia (eg, heart block \[second or third degree\], atrial fibrillation requiring therapy, ventricular fibrillation, ventricular tachycardia, supraventricular tachycardia, or cardiac arrest).~   Note \[history of intermittent atrial fibrillation not requiring treatment was allowed\].~10. Subject had a prior history of stroke and/or transient ischemic attack (TIA).~11. Subject had aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN) at Screening.~12. Subject had a prior history of (or current) malignancy; the one exception is a prior history of resected basal cell carcinoma.~13. Subject had previously received treatment with AVR-RD-01 or any other gene therapy.~Other inclusion/exclusion criteria apply.

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Single Assignment AVR-RD-01 (Type: EXPERIMENTAL): AVR-RD-01 is an autologous CD34+-enriched cell fraction transduced with LV/AGA containing an RNA transcript that, after reverse transcription, results in codon-optimized cDNA that, upon its integration into the human genome, encodes for functional human AGA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Program for Screening and Prevention of Eating Disorders in Obese Young People in Vulnerable Neighborhoods of Marseille: an Action Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria :~* Boys or girls aged 11 to 17~* Reside in the territory of intervention of the mobile team, i.e the 3rd, 14th, 15th and 16th arrondissement of Marseille, districts said to be vulnerable by the city's policy.~* Body mass index greater than or equal to IOTF-30 (HAS, 2011)~* Social precariousness score EPICES greater than or equal to 30riteria:~* Diagnosed Eating Disorder without medical and/or multi-professional care~Exclusion Criteria:~* Child with major difficulty of behavior~* Patient with medical care

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Obese Children in precarious situations (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All children aged 1-10 years, presenting to initial intake appointment with the Pediatric Gastroenterology Feeding Team Clinic at the Children's Hospital of Wisconsin (CHW), with BMI Z score of \< or equal to 0 (normal WHO BMI defined as Z score of -1 to 1), who have a parent willing to participate, will qualify for inclusion in the study. Children with vomiting due to presumed volume intolerance may be included in the study.~Exclusion Criteria:~* Untreated organic disease Anatomical barrier to swallowing or known swallowing disorder Diagnosis of severe developmental delay or mental retardation Significant brain pathology or seizure disorder that may affect oropharyngeal motor skills On medication with known effects on appetite or interactions with cyproheptadine

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- No Cyproheptadine treatment (Type: NO_INTERVENTION): Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
- Continuous Cyproheptadine (Type: EXPERIMENTAL): Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
- Cycled Cyproheptadine (Type: EXPERIMENTAL): Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with indications for AmB treatment~Exclusion Criteria:~* Patients with acute kidney injury~* Hyperkalemia ≥5.2~* Hypersensibility to spironolactone~* HIV infection~* Pregnant women~* Solid organ transplant~* Hemodynamic instability~* CKDEPI ≤30ml/min/1.73m3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone 200mg (Type: EXPERIMENTAL): Spironolactone 100 mg twice a day orally
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice a day orally
- Spironolactone 100mg (Type: EXPERIMENTAL): Spironolactone 100mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 18 and 50 years of age (with onset before age 40)~* Presence of chronic plaque type psoriasis unresponsive to treatment with topical preparations and extensive enough to consider appropriateness of systemic therapy~* Guttate forms of psoriasis~* Non-responsive to treatment or worsening of the pre-existing psoriasis~* With the exception of their skin disease , in good general state of health based on a complete medical history, blood test and urine analysis.~* Females must have negative urine pregnancy test and willing to take additional measures to keep from becoming pregnant during the course of the study~* No systemic prescription medication to control psoriasis within past 30 days~* Free of any topical antipsoriatic preparation for the duration of the study with the exception of emollients and moisturizers~Exclusion Criteria:~* Pustular forms of psoriasis, either localized or generalized~* Generalized Erythrodermic psoriasis~* Only palmoplantar psoriasis~* Only scalp psoriasis~* Only nail psoriasis~* Only inverse psoriasis~* Diabetes or impaired glucose tolerance~* History of recurrent yeast infections~* History of hypersensitivity to Penicillin~* History of severe adverse drug reactions~* Pregnancy~* Lactation~* HIV/AIDS~* History of renal disease~* History of liver disease~* History or presence of alcohol and/or drug dependence or abuse~* History of significant psychiatric illness~* History of allergy, asthma, allergic rhinitis, or urticaria subjects in other research trials, at least 30 days prior to the beginning of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented non-small cell carcinoma of the lung diagnosed within 16 weeks prior to study enrollment.~* Patient must be at least 18 years old at the time of consent.~* Stage III A or III B disease.~* Patients must be able to start study treatment within 6 weeks of study enrollment.~* Induction chemotherapy is allowed.~* Marginally resectable or unresectable at presentation.~* If the patient had exploratory thoracotomy, it must be done at least 3 weeks prior to enrollment.~Exclusion Criteria:~* Evidence of distant metastasis.~* Prior thoracic radiotherapy.~* Any history of allergic reaction to taxanes.~* Prior tumor resection. Candidate for upfront curative surgery.~* Pleural effusion visible on chest x-ray or the scout view of the CT chest.~* Unintentional weight loss within the month prior to diagnosis ≥ 10%.~* Previous or concomitant malignancy other than early stage tumor treated more than 3 years ago for cure.~* The presence of PET positive contralateral hilar disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET positive nodal disease measuring 15 mm or greater (Type: EXPERIMENTAL): Proton radiation with concomitant chemotherapy
- PET positive nodal disease measuring less than 15 mm (Type: EXPERIMENTAL): Proton radiation
- Patients considered resectable (Type: EXPERIMENTAL): Proton radiation plus surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Electrical and Formocresol Pulpotomy in Primary Molars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Restorable carious primary molars with reversible pulpitis and free of clinical or radiographic signs of pulp pathology~2. Males and females~3. Children ages 3-8 years old~4. Children classified under ASA I or II status~Exclusion Criteria:~1. Excluded will be primary molars with clinical or radiographic signs of pathology~2. Children not within age range~3. Absence of parent/caregiver~4. Mentally disabled parent/caregiver~5. Patients not returning for 6 month and 12 month follow up examination appointment

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- Formocresol (control) (Type: PLACEBO_COMPARATOR): This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
- Laser (Type: ACTIVE_COMPARATOR): This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* currently be treated at a University of MS Medical Center Internal Medicine Clinics~* currently taking metoprolol succinate for hypertension~* have their hypertension controlled (\<140/90).~Exclusion Criteria:~* uncontrolled hypertension~* severe renal or moderate hepatic impairment~* currently taking CYP 2D6 inducers/inhibitors~* recent stroke (less than 6 months)~* recent myocardial infarction (less than 6 months)~* congestive heart failure~* diagnosed obstructive sleep apnea~* atrial fibrillation~* arm circumference \>50 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoprolol to nebivolol (Type: EXPERIMENTAL): metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues